A California-based supplement maker has pulled its honey product from the market after federal regulators discovered an undeclared prescription drug ingredient in the mix.
Eros Apothecary initiated a voluntary recall of its Candy Power For Man Organic Honey after laboratory testing by the U.S. Food and Drug Administration identified the presence of tadalafil, a medication commonly used to treat erectile dysfunction. The agency published the recall notice on its website, warning consumers that the product poses a health risk because the ingredient is not listed on the label and could interact with other medications.
“The recall was initiated after FDA laboratory testing identified undeclared tadalafil,” the notice stated. Tadalafil is a phosphodiesterase-5 inhibitor that requires a prescription and should not be taken without medical supervision, particularly by individuals with cardiovascular conditions or those taking nitrates, as it can cause dangerous drops in blood pressure.
The FDA said the affected product was sold through eBay between April 27 and July 20. The packaging is described as yellow and orange, with the brand name prominently displayed. Consumers who purchased the item are urged to stop using it immediately and to dispose of any remaining product.
“Consumers should stop using Candy Power For Man immediately and dispose of any remaining product,” the notice continued.
The agency also advised anyone who has experienced adverse health effects after using the supplement to consult their healthcare provider. Symptoms of tadalafil exposure may include headache, flushing, dizziness, or more severe cardiovascular events, especially in vulnerable populations.
This recall is part of a broader pattern of FDA enforcement against dietary supplements that contain hidden pharmaceutical ingredients. Earlier this year, regulators escalated a plant butter recall to Class II risk, and a Walmart fruit cocktail recall expanded amid lead contamination concerns. In another case, the FDA flagged a blood pressure medication recall as Class II, highlighting the agency's vigilance over product safety.
The recall does not affect other Eros Apothecary products, according to the company, but the FDA is urging retailers and online marketplaces to remove the recalled lot from their listings. Consumers with questions can contact the company directly, though no contact information was provided in the initial notice.
This incident underscores the risks of purchasing dietary supplements from unregulated online channels, where product integrity may not be verified. Health experts advise consumers to check FDA recall announcements and to be wary of products that promise rapid or dramatic effects, as they may contain undisclosed active ingredients.
